SIRT1 in Cardiac Diseases: Molecular Mechanisms, Therapeutic Potential, and Future Directions.

May 27, 2026International journal of molecular sciences

SIRT1’s role, treatment possibilities, and future outlook in heart diseases

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

Sirtuin 1 (SIRT1) is associated with protective effects in cardiac tissue across various heart diseases.

SIRT1 plays a critical role in regulating metabolic and stress responses in the cardiovascular system.
It is involved in cardioprotection against conditions like myocardial ischemia/reperfusion injury and heart failure.
Mechanisms of SIRT1 include activation of antioxidant defenses, suppression of inflammation, and inhibition of cell death.
Natural compounds and synthetic SIRT1 activators may reduce cardiac injury and enhance heart function in preclinical studies.
SIRT1 could serve as a prognostic biomarker for heart failure and diabetes patients.
Excessive SIRT1 activity may have harmful effects, indicating the need for careful modulation.

AI simplified

Sirtuin 1 (SIRT1), a nicotinamide adenine dinucleotide (NAD)-dependent class III histone deacetylase, functions as a central metabolic sensor and stress-responsive regulator in the cardiovascular system. Unlike its well-characterized role in atherosclerosis, SIRT1 exerts multifaceted protective effects directly on cardiac tissue. This review synthesizes recent advances in understanding SIRT1-mediated cardioprotection across a spectrum of heart diseases, including myocardial ischemia/reperfusion (I/R) injury, heart failure (HF), diabetic cardiomyopathy (DCM), cardiac hypertrophy, aging-related cardiac dysfunction and circadian rhythm disruption. Mechanistically, SIRT1 orchestrates antioxidant defense through nuclear factor erythroid 2-related factor 2 (Nrf2) and Forkhead box O (FoxO) transcription factors activation, suppresses inflammatory signaling via nuclear factor kappa B (NF-κB) deacetylation, inhibits apoptosis by targeting p53, promotes autophagic flux and mitophagy, regulates mitochondrial biogenesis through peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), and controls ferroptosis via the Nrf2/glutathione peroxidase 4 (GPX4) axis. Preclinical studies demonstrate that natural compounds (resveratrol, quercetin, curcumin, ginsenosides, tanshinone IIA, bergenin, swietenine) and synthetic SIRT1 activators (SRT1720, anilinopyridine derivatives) attenuate cardiac injury and improve function. Moreover, SIRT1 serves as a prognostic biomarker in HF and diabetic patients. However, context-dependent dual roles, where excessive SIRT1 expression may be detrimental, underscore the need for precise modulation. Challenges remain in achieving cardiac-specific targeting, optimizing NADavailability, and translating preclinical findings into clinical practice. Future research should integrate multi-omics approaches, single-cell transcriptomics, and precision medicine strategies to unlock the therapeutic potential of SIRT1 in cardiac diseases. + +

Full Text

We can’t show the full text here under this license. Use the link below to read it at the source.

View on DOI ↗View on PubMed ↗

SIRT1 in Cardiac Diseases: Molecular Mechanisms, Therapeutic Potential, and Future Directions.

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief